Treatment | PC-3% survival | FR generated% of control | LXA4 levels% of control | IL-6% of control | TNF-α% of control |
---|---|---|---|---|---|
Control | 100 ± 1.86 | 100 ± 2.09 | 100 ± 2.60 | 100 ± 0.07 | 100 ± 6.34 |
LA 50 μM | 105.00 ± 1.81* | 104.31 ± 6.33* | 56.00 ± 6.61*** | 67.06 ± 6.11** | 53.75 ± 6.67*** |
LA 150 μM | 95.00 ± 4.62* | 102.65 ± 6.77* | 72.00 ± 4.00** | 71.18 ± 4.58** | 71.25 ± 3.97** |
GLA 25 μM | 88.61 ± 4.39* | 68.49 ± 3.35** | 187.49 ± 2.11*** | 158.71 ± 9.66*** | 137.00 ± 3.94** |
GLA 50 μM | 82.53 ± 3.72** | 74.67 ± 2.34** | 179.34 ± 0.79*** | 148.57 ± 8.14*** | 148.81 ± 4.64*** |
GLA 75 μM | 67.74 ± 3.81*** | 58.97 ± 5.11*** | 200.20 ± 2.94*** | 174.32 ± 7.32*** | 259.95 ± 6.95*** |
AA 50 μM | 80.35 ± 1.21** | 55.81 ± 2.99*** | 108.90 ± 0.39* | 100.66 ± 5.24 | 73.22 ± 0.91** |
AA 100 μM | 60.08 ± 4.04*** | 76.32 ± 3.80** | 99.17 ± 1.07 | 98.22 ± 1.32 | 65.50 ± 1.28** |
ALA 50 μM | 93.14 ± 1.66* | 112.27 ± 6.82* | 56.41 ± 5.44*** | 57.14 ± 4.58*** | 75.00 ± 3.90** |
ALA150μM | 70.59 ± 1.51** | 160.86 ± 7.10*** | 48.72 ± 6.92*** | 45.71 ± 7.70*** | 83.75 ± 6.54** |
EPA 50 μM | 83.36 ± 6.65** | 90.84 ± 6.30* | 88.50 ± 0.75* | 97.77 ± 2.13 | 80.41 ± 3.29** |
EPA 100 μM | 77.83 ± 5.55** | 76.98 ± 4.97** | 89.54 ± 1.22* | 101.33 ± 5.59 | 81.13 ± 1.00** |
DHA 50 μM | 88.94 ± 6.91* | 80.99 ± 2.88** | 81.43 ± 1.09** | 67.64 ± 1.95** | 69.14 ± 2.85** |
DHA100μM | 75.88 ± 3.55** | 67.00 ± 6.24** | 76.84 ± 0.69** | 57.71 ± 2.78*** | 66.69 ± 1.60** |